International Cancer Biomarker Consortium
The goal of the International Cancer Biomarker Consortium (ICBC) is to advance medical research and improve patient outcomes by discovering biomarkers (indicators) for multiple types of cancer. The consortium is focusing on biomarkers for the assessment of disease risk, early detection of disease, therapeutic prognosis, and response to treatment as well as disease recurrence.
Through a large-scale effort similar to the Human Genome Project, the consortium aims to make significant progress in the discovery of biomarkers by facilitating highly coordinated research and by leveraging resources and expertise from around the world to overcome the current obstacles in biomarker research. Each international team will choose a cancer site(s) for study, function independently, and secure its own funding. At the same time, the ICBC will provide a structure for international teams to work together on global issues such as adoption of data standards and the sharing data as well as on scientific details such as the logistics of tissue sample sharing and investigation of mouse models of cancer. Fred Hutchinson Cancer Research Center will coordinate the research endeavor by providing bioinformatics resources including software and tools for data management including storage, organization, analysis, and sharing.
Under the leadership of Dr. Lee Hartwell, President and Director of Fred Hutchinson Cancer Research Center, the ICBC is pioneering a new model for biomarker discovery and developing technologies and methodologies to make it possible. The Consortium has a Steering Committee that includes prominent leaders in proteomics.
Finding the Information You Need
Quick Links |
News
|
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.
